NCT01554124View on ClinicalTrials.gov

Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age With Probable and Confirmed Meningitis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Meningitis
Interventions
DRUG

Meropenem

"40 mg/kg every 8 hours (every 12 hours in the youngest age group: \< 32 weeks GA and \< 2 weeks postnatal age).~Treatment duration = 21 ± 7 days"

Trial Locations (1)

SW17 ORE

HEATH, Paul, London

All Listed Sponsors
collaborator

Chiesi Farmaceutici S.p.A.

INDUSTRY

lead

PENTA Foundation

NETWORK

NCT01554124 - Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age With Probable and Confirmed Meningitis | Biotech Hunter | Biotech Hunter